Is a higher dose automatically more effective?

No. Receptor-mediated effects saturate, so additional drug produces progressively less additional effect while adverse effects may keep rising.

What is a phase 3b trial?

A randomised trial run after the pivotal programme, often post-approval, addressing questions registration did not — such as a new dose.

Why does the estimand matter here?

A higher dose can improve results among those who stay on it while worsening them across everyone randomised, if discontinuation rises.

GLP-1 & Incretin Science

STEP UP: Testing Whether More Dose Means More Effect

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

STEP UP, registered as NCT05646706, was a completed phase 3b trial of once-weekly semaglutide 7.2 mg in 1,407 adults with obesity — three times the standard 2.4 mg weight-management dose. Wharton and colleagues published it in Lancet Diabetes and Endocrinology in November 2025.

Key facts

Registration: NCT05646706
Acronym: STEP UP
Phase: 3b
Status: Completed
Enrolment: 1,407
Dose tested: 7.2 mg once weekly
Standard dose: 2.4 mg for weight management
Published: Lancet Diabetes Endocrinol, Nov 2025

Why the question is not obvious

Receptor-mediated effects saturate. Once most receptors are occupied most of the time, adding more drug produces progressively less additional effect while adverse effects, which may follow different dose-response relationships, can continue rising. Whether a higher dose helps is therefore an empirical question about where the curve flattens, not an assumption.

What a phase 3b trial is

Phase 3b studies run after the pivotal trials and often after approval, addressing questions the registration programme did not — a new dose, a new population, a comparison the label does not cover. They are proper randomised trials, and they exist because approval settles fewer questions than it appears to.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

Why the dose ceiling matters commercially

Semaglutide at 2.4 mg reported 13.7% in the SURMOUNT-5 head-to-head against tirzepatide's 20.2%. If a higher dose closes part of that gap, the competitive position changes without a new molecule. That is a considerably cheaper route to a better number than developing a new compound, which is why the trial was worth running.

The tolerability trade-off

Gastrointestinal adverse effects are the dose-limiting factor across this class, and they follow from GLP-1 receptor pharmacology itself rather than from any impurity or design flaw. Any dose increase has to be read alongside what happened to discontinuation, because a dose producing more weight reduction in those who tolerate it can produce less across everyone assigned to it.

Why this is the estimand question again

Precisely the situation the efficacy and treatment-policy estimands separate. The efficacy estimand answers what a higher dose does in people who stay on it; the treatment-policy estimand answers what it does across everyone randomised, including those who stopped. A higher dose can improve the first and worsen the second, and a single headline figure conceals which.

What this does not concern

Research material, and it is not dosing guidance for anything. Semaglutide is a licensed medicine and 7.2 mg is a dose arm in a registered trial conducted under clinical supervision. Nothing supplied here is semaglutide or an alternative to it.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is a higher dose automatically more effective?: No. Receptor-mediated effects saturate, so additional drug produces progressively less additional effect while adverse effects may keep rising.
What is a phase 3b trial?: A randomised trial run after the pivotal programme, often post-approval, addressing questions registration did not — such as a new dose.
Why does the estimand matter here?: A higher dose can improve results among those who stay on it while worsening them across everyone randomised, if discontinuation rises.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum